JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in CD𝟖⁺ T Cells in Renal Cell Carcinoma Patients

Figure 2

IFN-𝛾 ELISPOT analyses of RCC-specific CD8⁺ T cell responses after MLTC. RCC1 CD8⁺ T cells stimulated by MLTC were tested for their reactivity against HLA-matched target cells such as autologous RCC, PTEC, and PHA-activated PBMC, (a). In panels (b), (c), and (d), K562 cells served as targets. A paired 𝑡-test analysis was used to compare the frequencies of autologous responder-CD8⁺ T cells versus allogenic responder-CD8⁺ T cells generated from the patient’s sibling (^∗𝑃<.05) and unrelated donor (^§P <.03), stimulated with RCC1 line. The HLA restriction of the anti-RCC T cell response was determined by addition of blocking mAbs specific for total HLA-class I, HLA-A24, HLA-A3, or HLA-B/-C alleles. Results represent the average (± SD) of triplicate wells and the presented data derive from 1 representative experiment of 5 performed.

(a)

(b)

(c)

(d)